Literature DB >> 28625360

Hypoxia primed placental mesenchymal stem cells for wound healing.

Suja Ann Mathew1, Bhawna Chandravanshi1, Ramesh Bhonde2.   

Abstract

AIMS: To investigate how Placental Mesenchymal Stem Cells (P-MSCs) would adapt themselves and survive under hypoxic conditions which are prevalent in most injury sites. MAIN
METHODS: P-MSCs were isolated from term placenta and characterised under normoxia and hypoxia (2-2.5% O2). Cells were examined for morphology and surface marker variations by flow cytometry analysis. Glucose stimulated insulin secretion was assayed by Insulin ELISA Kit. Gene expression levels were estimated using Real Time PCR for hypoxia inducible factor1 alpha, Insulin (INS), Glucose transporters (GLUT-1, GLUT-2 and GLUT-3), Adhesion Proteins- Integrins, Fibronectin1 (FN1), E-Cadherin (CDH1), and N-Cadherin (CDH2) and angiogenesis marker VEGFA. Immunofluorescence assay was done to confirm the presence of C-Peptide, GLUT 2, E-Cadherin and ITGB3. Adhesion was confirmed assessed on fibronectin binding. KEY
FINDINGS: We show that insulin secretion is not hampered under hypoxia. We found an upregulation of glucose transporters under hypoxia indicating enhanced glucose uptake needed to cater to metabolic demands of proliferating cells. Up regulation of adhesion molecules was seen under hypoxia indicative of a favoured environment for retention of cells at the injury site. We also found increased level of angiogenesis of P-MSCs under hypoxia. SIGNIFICANCE: Our present study thus demonstrates for the first time that P-MSCs modulate themselves under hypoxic conditions by secreting insulin, up regulating glucose transporters and adhesion molecules and eventually exhibiting an increased angiogenic potential. We thus infer that priming P-MSCs under hypoxia, could make them more suitable for wound healing applications.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28625360     DOI: 10.1016/j.lfs.2017.06.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

Review 1.  Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.

Authors:  Suja Ann Mathew; Charuta Naik; Paul A Cahill; Ramesh R Bhonde
Journal:  Cell Mol Life Sci       Date:  2019-08-29       Impact factor: 9.261

2.  [In vitro fertilization-embryo transfer affects focal adhension kinase signaling pathway in early placenta].

Authors:  L Zhao; L F Sun; X L Zheng; J F Liu; R Zheng; Y Wang; R Yang; L Zhang; L Yu; H Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-02-18

Review 3.  State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.

Authors:  Evan Paul Tracy; Virginia Stielberg; Gabrielle Rowe; Daniel Benson; Sara S Nunes; James B Hoying; Walter Lee Murfee; Amanda Jo LeBlanc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

4.  Human placental mesenchymal stromal cell therapy restores the cytokine efflux and insulin signaling in the skeletal muscle of obesity-induced type 2 diabetes rat model.

Authors:  Nagasuryaprasad Kotikalapudi; Samuel Joshua Pragasam Sampath; Sukesh Narayan Sinha; R Bhonde; Sathish Kumar Mungamuri; Vijayalakshmi Venkatesan
Journal:  Hum Cell       Date:  2022-01-29       Impact factor: 4.174

5.  Placental mesenchymal stem cells restore glucose and energy homeostasis in obesogenic adipocytes.

Authors:  Nagasuryaprasad Kotikalapudi; Samuel Joshua Pragasam Sampath; Sukesh Narayan Sinha; Bhonde R; Sathish Kumar Mungamuri; Vijayalakshmi Venkatesan
Journal:  Cell Tissue Res       Date:  2022-10-13       Impact factor: 4.051

Review 6.  Significance of Placental Mesenchymal Stem Cell in Placenta Development and Implications for Preeclampsia.

Authors:  Yang Zhang; Yanqi Zhong; Li Zou; Xiaoxia Liu
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

Review 7.  Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.

Authors:  Nádia de Cássia Noronha; Amanda Mizukami; Carolina Caliári-Oliveira; Juçara Gastaldi Cominal; José Lucas M Rocha; Dimas Tadeu Covas; Kamilla Swiech; Kelen C R Malmegrim
Journal:  Stem Cell Res Ther       Date:  2019-05-02       Impact factor: 6.832

8.  JMJD6 Dysfunction Due to Iron Deficiency in Preeclampsia Disrupts Fibronectin Homeostasis Resulting in Diminished Trophoblast Migration.

Authors:  Sruthi Alahari; Abby Farrell; Leonardo Ermini; Chanho Park; Julien Sallais; Sarah Roberts; Taylor Gillmore; Michael Litvack; Martin Post; Isabella Caniggia
Journal:  Front Cell Dev Biol       Date:  2021-05-12

Review 9.  The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke.

Authors:  Catriona J Cunningham; Elena Redondo-Castro; Stuart M Allan
Journal:  J Cereb Blood Flow Metab       Date:  2018-05-17       Impact factor: 6.200

Review 10.  Engineering mesenchymal stem cells to improve their exosome efficacy and yield for cell-free therapy.

Authors:  Jennifer Phan; Priyadarsini Kumar; Dake Hao; Kewa Gao; Diana Farmer; Aijun Wang
Journal:  J Extracell Vesicles       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.